$ABOS insider trading
Over the last 12 months, Acumen Pharmaceuticals insiders reported no purchases and 21 sales totaling $625K across SEC Form 4 filings. 90% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $625K 21 events
- Events · 12m
- 21 Form 4 filings, grouped
- Insiders · 12m
- 9 distinct reporters
- 10b5-1 share
- 90% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Porter DerrellD | ▼ Sale | 32,300 | $2.33 | $75K | -47.6% | 3 tranches |
| Jun 9, 2026 | Fountain Nathan BD | ▼ Sale | 6,400 | $2.23 | $14K | -11.7% | — |
| Mar 6, 2026 | Meisner Derek MChief Legal Officer & Corp Sec · O | ▼ Sale | 2,090 | $3.26 | $7K | -1.2% | plan |
| Feb 27, 2026 | Meisner Derek MChief Legal Officer & Corp Sec · O | ▼ Sale | 9,406 | $3.01 | $28K | -5.1% | plan |
| Jan 28, 2026 | Meisner Derek MChief Legal Officer & Corp Sec · O | ▼ Sale | 17,756 | $3 | $53K | -9.3% | plan · 2 tranches |
| Jan 23, 2026 | Meisner Derek MChief Legal Officer & Corp Sec · O | ▼ Sale | 8,934 | $1.87 | $17K | -4.9% | plan · 3 tranches |
| Jan 22, 2026 | Siemers EricChief Medical Officer · O | ▼ Sale | 3,226 | $1.81 | $6K | -1.2% | plan · 2 tranches |
| Jan 22, 2026 | Zuga MattCFO & Chief Business Officer · O | ▼ Sale | 4,160 | $1.83 | $8K | -1.3% | plan · 2 tranches |
| Jan 22, 2026 | OConnell Daniel JosephChief Executive Officer · O·D | ▼ Sale | 12,035 | $1.83 | $22K | -1.3% | plan · 2 tranches |
| Jan 22, 2026 | Barton RussellChief Operating Officer · O | ▼ Sale | 2,777 | $1.81 | $5K | -1.3% | plan · 2 tranches |
| Jan 12, 2026 | Meisner Derek MChief Legal Officer & Corp Sec · O | ▼ Sale | 50,659 | $1.8 | $91K | -37.7% | plan · 4 tranches |
| Jan 12, 2026 | OConnell Daniel JosephChief Executive Officer · O·D | ▼ Sale | 26,472 | $1.77 | $47K | -4.3% | plan · 3 tranches |
| Jan 8, 2026 | Zuga MattCFO & Chief Business Officer · O | ▼ Sale | 6,888 | $1.82 | $13K | -3.2% | plan |
| Jan 8, 2026 | Barton RussellChief Operating Officer · O | ▼ Sale | 3,530 | $1.86 | $7K | -2.8% | plan |
| Jan 8, 2026 | Doherty James J.President and CDO · O | ▼ Sale | 8,167 | $1.85 | $15K | -13.1% | plan · 2 tranches |
| Jan 7, 2026 | Schacterle AmyChief Regulatory Officer · O | ▼ Sale | 1,097 | $1.98 | $2K | -12.5% | plan |
| Jan 7, 2026 | Zuga MattCFO & Chief Business Officer · O | ▼ Sale | 14,905 | $1.97 | $29K | -6.4% | plan · 4 tranches |
| Jan 7, 2026 | OConnell Daniel JosephChief Executive Officer · O·D | ▼ Sale | 47,506 | $1.98 | $94K | -7.1% | plan · 3 tranches |
| Jan 7, 2026 | Meisner Derek MChief Legal Officer & Corp Sec · O | ▼ Sale | 26,668 | $1.98 | $53K | -16.6% | plan · 5 tranches |
| Jan 7, 2026 | Barton RussellChief Operating Officer · O | ▼ Sale | 9,318 | $1.97 | $18K | -6.8% | plan · 3 tranches |
| Jan 6, 2026 | Siemers EricChief Medical Officer · O | ▼ Sale | 10,834 | $1.96 | $21K | -6.4% | plan · 2 tranches |
Every $ABOS filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Acumen Pharmaceuticals filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ABOS feed.